Illumina Responds to Positive Updates from Chinese Ministry of Commerce

Illumina Responds to Positive Updates from Chinese Ministry of Commerce

- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requiring government approval for instrument purchases.

Illumina remains focused on achieving a positive resolution regarding its inclusion on the UEL and is committed to serving customers in this important market. For two decades, Illumina has been proud to partner with customers in China to advance genomics and improve human health.

"We are pleased with the announcement from MOFCOM, which is a very positive step forward. Illumina will continue to engage with authorities and stakeholders as we work toward a long-term resolution," said Jacob Thaysen, CEO of Illumina. "I want to thank our customers for their trust and support, and our team in China and around the world for their dedication and resilience."

Illumina is making no change to FY25 guidance, which was recently updated during the company's Q3 2025 earnings call.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

Cision View original content:https://www.prnewswire.com/news-releases/illumina-responds-to-positive-updates-from-chinese-ministry-of-commerce-302606280.html

SOURCE Illumina, Inc.

News Provided by PR Newswire via QuoteMedia

ILMN
The Conversation (0)
KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24 to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market... Keep Reading...
Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemistry, XLEAP-SBS ™ into all reagents for its NextSeq ™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments. "We are excited... Keep Reading...
Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares

Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares

"When-issued" trading expected to begin on or about June 12, 2024 Record date for distribution of GRAIL shares will be June 13, 2024 Distribution date for GRAIL shares anticipated to be June 24, 2024 Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the... Keep Reading...
Illumina appoints Everett Cunningham Chief Commercial Officer

Illumina appoints Everett Cunningham Chief Commercial Officer

Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma - Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of... Keep Reading...
Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome approach for MRD Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based... Keep Reading...

Latest Press Releases

Related News